- Home
- V vs NVO Comparison
V vs NVO Comparison
Compare V & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | V | NVO |
|---|---|---|
| Founded | 1958 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.8B | 199.4B |
| IPO Year | 2007 | 2001 |
Fundamental Metrics
Financial Performance| Metric | V | NVO |
|---|---|---|
| Price | $378.75 | $47.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 11 |
| Target Price | ★ $394.18 | $51.00 |
| AVG Volume (30 Days) | 5.8M | ★ 10.3M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 0.80% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $21,846,000,000.00 | N/A |
| Revenue This Year | $13.85 | N/A |
| Revenue Next Year | $10.36 | $3.70 |
| P/E Ratio | $30.09 | ★ $13.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $293.89 | $35.12 |
| 52 Week High | $385.57 | $64.16 |
Technical Indicators
Market Signals| Indicator | V | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 52.23 |
| Support Level | $320.90 | $43.25 |
| Resistance Level | $385.57 | $48.23 |
| Average True Range (ATR) | 5.88 | 0.98 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 74.79 | 64.95 |
Price Performance
Historical ComparisonAbout V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.